Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pilot clinical trial on the efficacy and safety of IDRACARE® in moderate to severe symptoms of vulvovaginal atrophy. To assess the efficacy and safety of Idracare® in the treatment of symptoms of AVV (dryness and / or dyspareunia) associated with menopause.
Pilot clinical trial on the efficacy and safety of IDRACARE® in moderate to severe symptoms of vulvovaginal atrophy. To assess the efficacy and safety of Idracare® in the treatment of symptoms of AVV (dryness and / or dyspareunia) associated with menopause.
Open study with only one arm. The study has a total duration per patient of 3 months: initial visit (V1), a follow-up visit (V2) after 4 weeks of treatment and a final visit (V3) after 12 weeks of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Idracare | Experimental | The treatment will be applied 2 times a week, preferably at night before going to bed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Idracare | Device | Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy of Idracare® in the treatment of symptoms of vulvovaginal atrophy (VVA) | To evaluate the efficacy of the Idracare® gel as a treatment for the symptoms of VVA, the percentage of women who present changes in dryness and / or dyspareunia has been established as the main variable. | Through study completion, an average of 12 weeks |
| Safety of Idracare® in the treatment of symptoms of vulvovaginal atrophy (VVA) measuring the incidence, nature and severity of adverse events (AE). | To evaluate the safety of Idracare® gel, the incidence, nature and severity of adverse events (AE) will be studied. | Through study completion, an average of 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the effect of Idracare® gel using Bachmann Vaginal Health Index (BVHI). | Effect of Idracare® gel will be evaluated on vaginal health status using Bachmann Vaginal Health Index (BVHI). It consists of 5 domains that evaluate different parameters (elasticity, fluids, pH, epithelial integrity and moisture) scoring each one of them independently, considering the maximum score as the best vaginal health status. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Women with vulvovaginal atrophy
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Josep Combalia, MD | Procare health Iberia | Study Director |
| Fernando Losa, Doctor | Clínica Sagrada Familia | Principal Investigator |
| Santiago Palacios, Doctor | Instituto Palacios de Salud y Medicina de la Mujer | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clínica Sagrada Familia | Barcelona | 08022 | Spain | |||
| HM Gabinete Velázquez |
The study documentation will be shared after study completion
Not provided
Not provided
Not provided
Not provided
open study, only one arm
Not provided
Not provided
Not provided
Not provided
| 4 and 12 weeks |
| To evaluate the effect of Idracare® gel using vulvar health index (VHI). | Effect of Idracare® gel will be evaluated on vaginal health status using vulvar health index (VHI). It consists of 8 domains that evaluate different parameters: physiological state of the labia majora, labia minora, clitoris, urethra, coloration, elasticity / introitus, discomfort / pain and other findings) scoring each of them independently, considering the maximum score as the worse in vulvar health. | 4 and 12 weeks |
| To evaluate the effect of Idracare® gel using vaginal pH | Effect of Idracare® gel will be evaluated on vaginal health status using vaginal pH changes. A lower pH compared to basal is considered an improvement on vaginal health status. | 4 and 12 weeks |
| To evaluate the effect of Idracare® gel using maturation of vaginal epithelial cells. | Effect of Idracare® gel will be evaluated on vaginal health status using Maturation Index (MI). MI is the most commonly used index to assess hormonal status. It evaluates the percentage composition of the three large types of cells that make up the vaginal epithelium in the cytological samples obtained: parabasal, intermediate and superficial. It consists of selecting five fields at random (x 10 magnification) and counting 100 epithelial cells in each area, determining the percentage of superficial, intermediate and parabasal cells in each area. The result is expressed as% parabasal cells:% intermediate cells (navicular):% superficial cells. | 4 and 12 weeks |
| To evaluate the effect of Idracare® gel using vaginal microbiota. | Effect of Idracare® gel will be evaluated on vaginal health status using vaginal Dysbiosis test. It consists of analyzing by means of real time polymerase chain reaction (real time PCR) different microorganisms that are part of the vaginal ecosystem such as Lactobacillus species (L. crispatus, L. jensenii, L. iners, L. gasseri ), Candida species, lactic acid microbiota (Atopobium, Gardnerella), non-lactic acid microbiota and pathogens. | 4 and 12 weeks |
| The degree of satisfaction with the use of Idracare® | The degree of satisfaction with the use of Idracare® will be evaluated using a 7-point Likert-type scale, from 1 (satisfied) to 7 (not satisfied at all). | 4 and 12 weeks |
| The tolerability of the treatment using a 5-point Likert-type scale | The tolerability of the treatment will be evaluated using a 5-point Likert-type scale, from 1 (no problem with the treatment) to 5 (I can't stand the treatment) | 4 and 12 weeks |
| Madrid |
| 28001 |
| Spain |
| Instituto Palacios de Salud y Medicina de la Mujer | Madrid | 28009 | Spain |
| HU Miguel Servet | Zaragoza | 50009 | Spain |